Goldman Sachs Group Inc Alaunos Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.04 - $0.13 $1,717 - $5,581	-42,934 Reduced 80.86%	10,161 $0
Q3 2023 May 14, 2024	BUY	$0.12 - $0.5 $5,152 - $21,467	42,934 Added 422.54%	53,095 $6,000
Q3 2023 Nov 14, 2023	SELL	$0.12 - $0.5 $88 - $369	-738 Reduced 1.37%	53,095 $6,000
Q2 2023 May 14, 2024	SELL	$0.43 - $0.65 $1,405 - $2,124	-3,268 Reduced 5.72%	53,833 $27,000
Q2 2023 Aug 14, 2023	SELL	$0.43 - $0.65 $1,405 - $2,124	-3,268 Reduced 5.72%	53,833 $27,000
Q1 2023 May 14, 2024	SELL	$0.46 - $0.81 $53,325 - $93,899	-115,925 Reduced 67.0%	57,101 $35,000
Q1 2023 May 11, 2023	SELL	$0.46 - $0.81 $53,325 - $93,899	-115,925 Reduced 67.0%	57,101 $35,000
Q4 2022 May 14, 2024	SELL	$0.5 - $261.0 $47,079 - $24.6 Million	-94,159 Reduced 35.24%	173,026 $112,000
Q4 2022 Feb 13, 2023	SELL	$0.5 - $261.0 $47,079 - $24.6 Million	-94,159 Reduced 35.24%	173,026 $112,000
Q3 2022 May 14, 2024	BUY	$1.04 - $322.5 $81,209 - $25.2 Million	78,086 Added 41.29%	267,185 $460,000
Q3 2022 Nov 10, 2022	BUY	$1.04 - $322.5 $81,209 - $25.2 Million	78,086 Added 41.29%	267,185 $0
Q2 2022 May 14, 2024	BUY	$0.41 - $1.24 $73,364 - $221,883	178,938 Added 1761.03%	189,099 $0
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $1.79 Million - $5.42 Million	-4,367,410 Reduced 95.85%	189,099 $234,000
Q1 2022 May 16, 2022	BUY	$0.62 - $1.17 $2.52 Million - $4.76 Million	4,065,089 Added 827.21%	4,556,509 $2.97 Million
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $53,982 - $93,602	49,525 Added 11.21%	491,420 $536,000
Q3 2021 Nov 10, 2021	BUY	$1.44 - $2.73 $636,328 - $1.21 Million	441,895 New	441,895 $804,000

Others Institutions Holding TCRT

# of Institutions

Shares Held

92.6K

Call Options Held

Put Options Held

View Full List

About Alaunos Therapeutics, Inc.

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $398M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

More about TCRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account